GELF high-tumor-burden criteria (follicular lymphoma)
GELF high-tumor-burden criteria (Brice 1997): any of mass > 7 cm, ≥ 3 nodal sites > 3 cm, B symptoms, splenomegaly, effusion, cytopenias, or leukemic phase indicates treatment over observation.
Open the calculator → Runs in your browser. Data leaves only if you deliberately send a problem report from the interactive tool.
Example
- Largest nodal mass
- 8
- ≥ 3 nodal sites > 3 cm
- No
- B symptoms
- No
- Splenomegaly
- No
- Pleural / peritoneal effusion
- No
- Hemoglobin
- 12
- Platelets
- 220
- Leukemic phase
- No
Result: GELF high-tumor-burden criteria MET (1 criterion: mass > 7 cm) -- treatment is indicated rather than observation.
The tool opens with these values already filled in. Replace them with your own.
What the result means
- Not met
- No criterion present; low tumor burden, observation an option.
- Met
- Any one criterion present; high tumor burden, treatment indicated.
What you enter
- Largest nodal mass (cm)
- ≥ 3 nodal sites > 3 cm
- B symptoms
- Splenomegaly (below umbilicus)
- Pleural / peritoneal effusion
- Hemoglobin (g/dL)
- Platelets (×10⁹/L)
- Leukemic phase (> 5 ×10⁹/L circulating)
How this is calculated
Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires (GELF). J Clin Oncol. 1997;15(3):1110-1117. Read the source ↗
A reference and educational tool. Not medical, legal, or financial advice, and not a substitute for clinician judgment.